IL-SKYWORKS-AERONAUTICS
24.6.2021 14:17:11 CEST | Business Wire | Press release
Today, Skyworks Aeronautics (“Skyworks”) announces the order of 100 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from a consortium of Mint Air (“Mint”) and Mobius.energy Corp (“Mobius”) with options for an additional 100 aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005323/en/
“A consortium led by Mint Air is committed to bringing safe, efficient, and cost-effective electric aircraft solutions to South Korea and we are absolutely thrilled they have selected our eGyro as their aircraft of choice to initiate operation of the leading eVTOL service in Korea. We look forward to performing our first public demonstrations of the eGyro in Korea and to launching the eGyro Urban Air Mobility (UAM) platform in the Korean market,” said John Michel, Co-Founder & Executive Director of Skyworks.
“We are pleased to announce the Skyworks eGyro as the launch UAM platform for Mint Air. The fundamental safety and performance advantages of the eGyro will enable Mint Air to accelerate the adoption of intra and inter-city passenger transport in Korea,” said Eugene Choi, Chief Executive Officer of Mint Air.
The consortium led by Mint Air and Skyworks signed a Letter of Intent (LOI) for exclusive partnership in South Korea. The consortium will collaborate with Skyworks to develop a pilot training program and maintenance and repair capability in Korea for efficient operation of eGyro fleet.
The eGyro will leverage Mobius’ novel battery module architecture and low total cost of ownership providing power-as-a-service business model. “The high energy density, unmatched power boost, and outstanding thermal management of the Mobius battery modules support our efforts to produce an aircraft with best-in-class range and performance. We are excited to be the UAM launch platform for the Mobius battery module and service”, said Don Woodbury, Skyworks’ Co-Founder & Chief Technology Advisor.
Jongwon “JP” Park, Chief Strategy Officer and Co-Founder of Mobius said, “Mobius’ is building a global aviation battery alliance and our partnership with Skyworks to bring the eGyro to the Korean market marks an important milestone. Skyworks is the first of many customers who recognized the performance and safety of Mobius’ battery.”
About Mint Air
Mint Air is a startup company in stealth mode until now building an Advanced Air Mobility Service in South Korea. Mint Air’s approach is to facilitate an ecosystem of partners to accelerate the adoption of electric flight in Korea. A former global engineering part manufacturing company, Mint Air will take advantage of its global business experience and network to accelerate the development of the Urban Air Mobility ecosystem in Asia-Pacific markets. Beginning with air taxi operation, Mint Air aspires to become a global electric aircraft manufacturing company building electric aircraft supply chain, developing critical part manufacturing capability, and eventually assembling eGyro in Korea. For more information about the company, visit www.mintair.kr
About Mobius
Mobius.energy is developing safe, light, and energy-efficient novel battery module architecture. The module’s high discharge rate provides on-demand power boost needed during the take-off of electric aircraft at 7C which can last over 6 minutes. Its equally high charge rate enables fast charging in less than 10 minutes. Its light, simple, and compact design enables easy maintenance, on-site swapping, and cost-effective re-use and recycling. Mobius’ goal is to build battery subscription, maintenance, and salvage service including the second life repurpose and the end-of-life recycling of batteries to enable circular economy and thereby contribute to decarbonization of the aviation industry. For more information about the company, visit www.mobius.energy
About Skyworks Aeronautics
Skyworks Aeronautics is the world leader in the science and technology of gyronautics, focusing on the design and development of high-performance gyroplanes. Skyworks gyroplanes provide more affordable, safer, and higher performance alternatives for runway-independent aircraft.
Skyworks has more than 40 patents with several more underway, all obtained in an effort to radically change not only the way gyroplanes are perceived, but also the way they are utilized. From mass personnel transportation, agriculture, defense, and border protection to changing the economies of developing nations, Skyworks' goal is to change the nature of vertical flight. For more information about the company, its products, and individual members of the Skyworks team, visit www.skyworks-aero.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005323/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
